RARE Daily

Every Cure and OpenEvidence Team Up to Find New Uses for Existing Drugs

November 17, 2026

Rare Daily Staff

Nonprofit biotech Every Cure is partnering with medical artificial intelligence company OpenEvidence to develop new uses for existing medicines, focusing on treatments that offer little financial incentive for drugmakers to pursue.

The collaboration aims to connect Every Cure’s drug-repurposing research with OpenEvidence’s AI tools and network of physicians. The organizations plan to use those connections to assess potential treatments, identify doctors with relevant expertise, help recruit patients for clinical trials and share study findings with clinicians.

The effort targets a gap in drug development: existing medicines may hold promise for diseases other than those for which they have been approved, but the potential financial return, particularly for generic drugs, may not justify a company’s investment in researching those uses.

Every Cure uses AI and data science to identify potential matches between approved medicines and diseases that need better treatments. Its broader mission is to advance promising candidates, particularly for rare, neglected and underserved conditions.

Under the partnership, OpenEvidence will help evaluate those proposed uses through its AI models and biomedical information resources. It will also help connect Every Cure with physicians who treat the diseases under investigation.

Those doctors can provide insights that are difficult to draw from published research alone, including how a disease progresses, where existing care falls short and which improvements would matter most to patients.

“Some of the most promising new uses for existing medicines are in diseases that few physicians ever see,” said Matt Goddeeris, Every Cure’s chief scientific officer. “OpenEvidence can help us reach the physicians who care for these patients.”
The partnership is intended to extend beyond identifying potential treatments. As Every Cure’s programs move into clinical trials, OpenEvidence will help physicians identify patients who may qualify. Treating doctors would decide whether to pursue a referral.

The organizations also plan to use the platform to share findings as studies produce results. The announcement did not identify the first drugs or diseases the partnership will investigate, provide a timetable for trials or disclose financial terms.

Every Cure’s approach grew out of co-founder and CEO David Fajgenbaum’s search for a treatment for his own life-threatening illness, idiopathic multicentric Castleman disease.

Fajgenbaum identified an overactive immune pathway in his blood and tried sirolimus, an existing medicine that targets the same pathway and is approved to prevent rejection after kidney transplantation. He has remained in remission for more than a decade. Every Cure was founded to make the search for such opportunities more systematic.

Repurposing can offer a head start because an approved drug is already manufactured and researchers have information about its safety. But an established use does not prove that a medicine will work—or be acceptably safe—for a different disease. Every Cure said it will generate evidence to assess those questions before working to address barriers to patient access.

“Physicians come to OpenEvidence for the best available evidence, but for thousands of diseases, that evidence doesn’t exist yet,” said Isabel Ostrer, OpenEvidence’s director of primary care initiatives. “Together with Every Cure, we can generate hypotheses and evidence to help patients who have exhausted all treatment options.”

Photo: Every Cure co-founder and CEO David Fajgenbaum’

 

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube